Nearly three-quarters of poorly controlled, type 2 diabetic patients reach glycemic targets when they are treated with biphasic insulin aspart 70/30 (NovoMixR), according to preliminary results released here at the 68th Annual Meeting of the American Diabetes Association (ADA).
The data are from the IMPROVETM trial, in which nearly 58,000 type 2 diabetics from eleven […]










